Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2175-2182

  Burch, Patrick A ^a   Breen, Jami K ^a   Buckner, Jan C ^a   Gastineau, Dennis A ^a   Kaur, Judith A ^a   Laus, Reiner L ^b   Padley, Douglas J ^a   Peshwa, Madhusudan V ^b   Pitot, Henry C ^a   Richardson, Ronald L ^a   Smits, Bouwien J ^b   Sopapan, Pitsata ^b   Strang, George ^b   Valone, Frank H ^b   Vuk Pavlović, Stanimir ^a  

^a MAYO CLINIC   (United States)

^b Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CYTOKINE ANTIBODY; HYBRID PROTEIN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ANTIBODY TITER; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; FATIGUE; FEVER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; INJECTION PAIN; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE SPECIFICITY;

ACID PHOSPHATASE; ANTIGEN-PRESENTING CELLS; CELL DIVISION; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034043167     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Landis, S., Murray, T., Bolden, S., and Wingo, P. Cancer Statistics 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Dowling, A. J., and Tannock, I. F. Systemic treatment for prostate cancer. Cancer Treat. Rev., 24: 283-301, 1998.
3. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160: 1230-1231, 1998.
4. Newling, D. W., Dennis, L., and Vermeylen, K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria for evaluation used in the European Organization for Research and Treatment of Cancer. Genitourinary Group Study, 30853. Cancer (Phila.), 72: 3793-3798, 1993.
5. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
6. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
7. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
8. Kundu, S. K., Engleman, E., Benike, C., Shapero, M. H., Dupuis, M., van Schooten, W. C., Eibl, M., and Merigan, T. C. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retrovir., 14: 551-560, 1998.
9. Gong, J., Chen, D., Kashiwaba, M., and Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med., 3: 558-561, 1997.
10. Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., Ricciardi-Castagnoli, P., Raposo, G., and Amigorena, S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med., 4: 594-600, 1998.
11. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380, 1996.
12. Segel, L. A., Jaeger, E., Elias, D., and Cohen, I. R. A quantitative model of autoimmune disease and T-cell vaccination: does more mean less? Immunol. Today, 16: 80-84, 1995.
13. Lotze, M. T., Shurin, M., Davis, I., Amoscato, A., and Storkus, W. J. Dendritic cell based therapy of cancer. Adv. Exp. Med. Biol., 417: 551-569, 1997.
14. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., Jaffe, E. S., Creekmore, S. P., Longo, D. L., and Kwak, L. W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med., 5: 1171-1177, 1999.
15. Solin, T., Kontturi, M., Pohlmann, R., and Vihko, P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analysis. Biochim. Biophys. Acta, 1048: 72-77, 1990.
16. Lam, K., Li, C., Yam, L., Sun, T., Lee, G., and Ziesmer, S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate, 15: 13-21, 1989.
17. Valone, F. H., Yang, D. M., Ruegg, C. L., Shaprro, M. H., Slagle, P. H., and Laus, R. Dendritic cell immunotherapy of prostate cancer: preclinical models of autoimmune prostatitis and early clinical experience. Exp. Haematol. Today, in press, 2000.
18. Valone, F. H., Small, E. J., Peshwa, M., Strang, G., Laus, R., Ruegg, C., and van Schooten, W. Immunotherapy of hormone refractory hormone cancer (HRPC) with prostate acid phosphatase (PAP)-loaded dendritic cells (APC8015). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 312a, 1999.
19. Tao, M. H., and Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (Lond.), 362: 755-758, 1993.
20. Fong, L., Ruegg, C. L., Brockstedt, D., Engleman, E. G., and Laus, R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol., 159: 3113-3117, 1997.
21. + cytotoxic T-lymphocytes in vitro using antigen presenting cells pulsed with prostatic acid phosphatase peptide. Prostate, 36: 129-138, 1998.
22. Lacy, M., Wettstein, P., Greipp, P. R., Fonseca, R., Dispenzieri, A., Rajkumar, S. V., Gastineau, D. A., Lust, J., Witzig, T., Valone, F., Kyle, R. A., and Gertz, M. A. Dendritic cell-based idiotype vaccination for post transplant multiple myeloma. Book of Abstracts, VII International Multiple Myeloma Workshop, p. 109. Stockholm: 1999.
23. Ridge, J. P., Di Rosa, F., and Matzinger, P. Superactivation of dendritic cells: a T helper's way of helping killers. Nature (Lond.), 393: 474-478, 1998.
24. Taussig, M. J. Induction of hapten-specific B cell tolerance by low doses of hapten-carrier conjugate. Nature (Lond.), 245: 34-36, 1973.
25. Gribben, J., Devereux, S., Thomas, N., Keim, M., Jones, H., Golstone, A., and Linen, D. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet, 335: 434-437, 1990.
26. Chen, T. T., and Levy, R. Induction of auto-antibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein. J. Immunol., 154: 3105-3117, 1995.
27. Thalmann, G. N., Sikes, R. A., Chang, S. M., Johnston, D. A., von Eschenbach, A. C., and Chung, L. W. K. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J. Natl. Cancer Inst., 88: 794-801, 1996.
28. Murphy, G. P., Priore, R. L., and Scardino, P. T. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus Adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project Randomized Trial. Urology, 32: 33-40, 1998.
29. Wozniak, A. J., Blumenstein, A. B., Crawford, E. D., Moileau, M., Rivkin, S. E., and Fletcher, W. S. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A South-west Oncology Group Study. Cancer (Phila.), 71: 3975-3978, 1993.